Free tools Windows power users keep installed
One-click scans. No signup required.
Tatiana Schlossberg revealed that she had acute myeloid leukemia (AML) with a rare inv(3) chromosomal rearrangement in a New Yorker essay published November 22, 2025. She had been diagnosed on May 25, 2024, hours after giving birth to her daughter. After chemotherapy, two stem-cell transplants, a CAR-T clinical trial, relapses and severe complications, Schlossberg died on December 30, 2025, at age 35.
Her family’s announcement did not specify a cause or location of death. Obituary reports said it followed her battle with AML. “Terminal” referred to the prognosis she described in her essay—not to a formal “stage 4” classification, which is generally not used for leukemia.
What Tatiana Schlossberg revealed
Tatiana Schlossberg publicly disclosed that she had acute myeloid leukemia (AML) with a rare chromosomal abnormality known as inv(3) in her first-person essay, “A Battle with My Blood,” published by The New Yorker on November 22, 2025. The diagnosis had been made about 18 months earlier, on May 25, 2024, shortly after she gave birth to her daughter.
Schlossberg described an unusually difficult course involving chemotherapy, two stem-cell transplants, relapses, serious infections, complications from treatment and participation in a CAR-T clinical trial. She wrote that her doctor believed the latest treatment might keep her alive for “a year, maybe.” Schlossberg died on December 30, 2025, at age 35. Her family announced her death without specifying a cause or location; obituary reports said it followed her battle with AML. Read Schlossberg’s essay in The New Yorker and see the later reporting from ABC News and The Washington Post.
What’s actually slowing this PC down?
Pick the symptom - the matching free tool is one click away.
#1 Best Overall
- Author: American Medical Association.
- Publisher: Wiley
- Pages: 1200
- Publication Date: 2004-08-01
- Edition: Fourth
How the leukemia was discovered after childbirth
Schlossberg’s daughter was born at 7:05 a.m. on May 25, 2024, at Columbia-Presbyterian Hospital in New York. Schlossberg had arrived roughly 10 minutes before the birth. Several hours later, while she was still receiving postpartum care, a doctor noticed that her blood count was highly abnormal.
Her white-blood-cell count was 131,000 cells per microliter. A typical reference range is approximately 4,000 to 11,000, although ranges vary somewhat by laboratory. Doctors initially considered whether the result could be connected with pregnancy or delivery, but the count led them to investigate leukemia. Schlossberg was diagnosed with AML at age 34.
The timing is important: her leukemia was detected after childbirth, but the public record does not establish that pregnancy or delivery caused it. A high white-cell count also should not automatically be described as a blast-cell count; the 131,000 figure was the total white-blood-cell count reported in her account.
What AML with inv(3) means
Acute myeloid leukemia is a cancer of blood-forming cells in the bone marrow. In AML, immature myeloid cells multiply abnormally and can crowd out the marrow’s ability to produce healthy red blood cells, platelets and infection-fighting white blood cells. The disease can therefore lead to anemia, infections, bleeding and other serious complications. The National Cancer Institute’s AML guidance explains that diagnosis and risk assessment depend on blood, bone-marrow, cytogenetic and molecular testing.
Schlossberg referred to her condition as a rare “Inversion 3” mutation. In medically precise terms, this is generally described as an inv(3)(q21.3;q26.2) chromosomal inversion, or a related t(3;3)(q21.3;q26.2) rearrangement. It involves the MECOM/EVI1 region and altered regulation involving GATA2. The NCI says this abnormality occurs in approximately 1% of AML cases and is associated with poor prognosis. The 2022 European LeukemiaNet recommendations classify inv(3)/MECOM abnormalities as adverse-risk genetic findings.
That risk classification provides medical context, but it is not a personal survival estimate. Schlossberg’s prognosis also depended on factors that are not fully public, including her complete molecular profile, treatment response, relapse pattern and transplant history.
Why the diagnosis was described as terminal
“Terminal” described Schlossberg’s individual clinical situation and the prognosis she reported receiving from her doctor. It was not the name of an AML stage. Leukemias are generally not assigned “stage 4” in the same way as many solid tumors such as breast or lung cancer; the American Cancer Society explains the difference between staging systems.
In Schlossberg’s case, the grave prognosis followed repeated disease recurrence and a complicated treatment history. She experienced temporary remissions, but the leukemia returned after treatment. Saying she was “cured” would therefore misrepresent her account.
Her chemotherapy, transplants and clinical trials
Schlossberg’s essay describes a sequence of intensive treatments:
- Initial hospitalization and chemotherapy: She spent approximately five weeks at Columbia-Presbyterian receiving treatment intended to reduce the leukemia in her bone marrow. After her blast-cell count fell, she was allowed to complete one round of treatment at home.
- Transfer for transplant care: She moved to Memorial Sloan Kettering Cancer Center for the next phase of treatment.
- First stem-cell transplant: Her sister was a match and donated the stem cells. The transplant initially put Schlossberg into remission.
- Relapse: The leukemia later returned.
- CAR-T clinical trial: Schlossberg received an experimental CAR-T approach using engineered T cells derived from her sister. In her case, the therapy was provided through a clinical trial, not as a routine or guaranteed AML cure.
- Cytokine-release syndrome: After the CAR-T treatment, she developed a serious immune reaction involving breathing problems, fluid in her lungs and liver complications. She entered remission again for a time.
- Second stem-cell transplant: She received stem cells from an unrelated male donor in his twenties from the Pacific Northwest.
- Further complications: She later developed graft-versus-host disease and an Epstein-Barr virus infection that severely affected her kidneys.
- Later trial treatment: During another clinical trial, her doctor told her the treatment might extend her life by roughly a year.
Stem-cell transplant is also called hematopoietic stem-cell transplant. It is closely related to what is often called a bone-marrow transplant, although the transplanted cells may be collected from the bloodstream rather than directly from bone marrow.
Rank #3
- essential home medical reference for family use
- Johns Hopkins Family Health Book, over 1600 pages
CAR-T therapy is an established platform for some blood cancers, but AML applications remain largely investigational and trial-based. NCI’s AML clinical-trial listings include early-stage CAR-T studies, including phase 1 research.
Her account of motherhood and family
The emotional center of Schlossberg’s essay was her fear that her children would grow up without enough memories of her. She worried that her son might remember only fragments and that her daughter, born just before the diagnosis, might not remember her as her mother.
The Tool Desk
Outbyte Driver Updater FREEScan for outdated or missing drivers - takes under a minuteDriver Scan →Outbyte PC Repair FREERepair Windows errors before they cause bigger problemsFix Now →Infection risks following transplantation also limited ordinary caregiving. Schlossberg wrote that for much of her daughter’s first year she could not change her diaper, bathe her or feed her. Her parents and siblings helped care for the children while she underwent treatment.
She also wrote about feeling that she was adding another tragedy to her mother’s life and to a family marked by earlier losses. Those passages should be understood as Schlossberg’s own account. They do not establish private emotions or experiences for Caroline Kennedy or other relatives beyond what Schlossberg described.
Why she criticized Robert F. Kennedy Jr.
The latter part of the essay criticized her cousin Robert F. Kennedy Jr., who was then secretary of Health and Human Services. Schlossberg argued that cuts to medical research, threats to clinical-trial infrastructure and vaccine skepticism could harm cancer patients and immunocompromised people.
She specifically raised concerns about the future of mRNA research, including possible cancer applications, and about access to vaccines for people whose immune systems have been weakened by treatment. She also wrote that misoprostol had been used to treat her postpartum hemorrhage and argued that the drug could become politically vulnerable because it is also associated with medication abortion.
These were Schlossberg’s political arguments, not claims that government policy caused her illness, changed her treatment or caused her death. Some surrounding policy developments can be independently documented:
- On August 5, 2025, HHS announced that it was winding down mRNA vaccine-development activities under BARDA and canceling or reducing related contracts and solicitations. HHS published the announcement here.
- Columbia University said that roughly $400 million in federal grants had been suspended in March 2025 before the university later reached an agreement with the administration. Columbia’s research-funding FAQ describes its account of the dispute.
Those developments provide context for Schlossberg’s concerns, but they do not show that every funding decision affected her personal care or that the policies had a direct role in her death.
Who Tatiana Schlossberg was
Schlossberg was more than a member of the Kennedy family. Born Tatiana Celia Kennedy Schlossberg in Manhattan on May 5, 1990, she was the daughter of Caroline Kennedy and designer Edwin Schlossberg, and the granddaughter of President John F. Kennedy and Jacqueline Kennedy Onassis. She was the sister of Rose Schlossberg and Jack Schlossberg.
She graduated from Yale University and earned a master’s degree from Oxford. She worked as a journalist for The New York Times and later as a freelance environmental reporter, writing about climate change, science and the environmental consequences of everyday choices.
Do these 3 things before closing this tab:
1Repair Windows errors before they cause bigger problems2Fix the driver behind crashes, sound loss and screen glitches3Clear out junk files and repair common Windows errorsBest Value
Her 2019 book, Inconspicuous Consumption: The Environmental Impact You Don’t Know You Have, examined the hidden environmental costs of ordinary products and habits. Her professional record helps explain why her final essay connected personal medical treatment with public research policy, vaccine debates and scientific institutions. The Washington Post obituary and the John F. Kennedy Library profile provide additional biographical context.
Independent reader supportYour contribution helps us test, update, and keep practical guides available for everyone.Publication and death timeline
| Date | What happened |
|---|---|
| May 5, 1990 | Tatiana Schlossberg was born in Manhattan. |
| May 25, 2024 | She gave birth to her daughter at Columbia-Presbyterian Hospital. Hours later, doctors found a white-blood-cell count of 131,000 per microliter. |
| May 2024 | She was diagnosed with AML involving the rare inv(3) abnormality. |
| 2024–2025 | She underwent chemotherapy, two stem-cell transplants, clinical-trial treatment, remissions, relapses and serious complications. |
| January 2025 | She entered a CAR-T clinical trial, according to the chronology of her essay; the essay itself says “In January” rather than giving a full date. |
| Early April 2025 | She underwent a second transplant from an unrelated donor; the year is inferred from the essay’s chronology. |
| Late September 2025 | She suffered a severe Epstein-Barr virus infection affecting her kidneys; the year is inferred from the publication chronology. |
| November 22, 2025 | The New Yorker published “A Battle with My Blood.” The print edition used the headline “A Further Shore.” The online publication date was also the 62nd anniversary of President Kennedy’s assassination. |
| December 30, 2025 | Her family announced that Schlossberg had died at age 35. |
What is confirmed—and what is not
- Confirmed by Schlossberg’s account: her AML diagnosis, the May 2024 discovery, the inv(3) abnormality, her treatment sequence, complications, family concerns and criticism of health-policy decisions.
- Confirmed by medical sources: AML affects blood-forming cells; inv(3)/MECOM abnormalities are rare and associated with adverse risk; AML is not generally staged like a solid tumor.
- Confirmed by official policy sources: HHS announced the 2025 changes to mRNA-development activities, and Columbia described the suspension and later resolution of federal grants.
- Reported after her death: Schlossberg died on December 30, 2025, at 35, after her battle with AML. Her family’s statement itself did not specify the cause.
There is no public evidence that childbirth, an environmental exposure, federal policy or any other single outside factor caused Schlossberg’s leukemia. Nor is there a basis for describing her illness as “stage 4,” claiming that CAR-T cured her, or turning her story into a so-called “Kennedy curse.”
Frequently Asked Questions
What type of cancer did Tatiana Schlossberg have?
Tatiana Schlossberg had acute myeloid leukemia, or AML, with a rare inv(3) chromosomal rearrangement involving the MECOM/EVI1 region. She described it in her New Yorker essay as “Inversion 3.”
When was Tatiana Schlossberg diagnosed?
Her leukemia was discovered on May 25, 2024, several hours after she gave birth to her daughter. The timing does not establish that childbirth caused the disease.
Quick wins for a faster PC:
Clear out junk files and repair common Windows errorsFree Scan →Fix the driver behind crashes, sound loss and screen glitchesFind Drivers →Repair Windows errors before they cause bigger problemsFix Now →What treatment did Tatiana Schlossberg receive?
She underwent chemotherapy, two stem-cell transplants, a CAR-T clinical trial and additional trial treatment. Her illness went into remission more than once but later relapsed.
Is Tatiana Schlossberg still alive?
She died on December 30, 2025, at age 35. Her family announced her death without specifying a cause; news obituaries reported that it followed her battle with AML.
The Bottom Line
Tatiana Schlossberg was diagnosed with high-risk acute myeloid leukemia involving an inv(3) chromosomal rearrangement after giving birth in May 2024. Her New Yorker essay described chemotherapy, two transplants, CAR-T trial treatment, relapses and severe complications. She died at 35 on December 30, 2025; her family did not state a cause, while obituary reports linked her death to her AML battle.
Quick Recap
Product prices and availability are accurate as of the date/time indicated and are subject to change. Any price and availability information displayed on Amazon at the time of purchase will apply.
